Decera Clinical Education Pharmacy Practice Podcast

In this episode, listen to Kelly Romo, PharmD, BCOP; and Shauna Kraft, PharmD, BCOP, share their takeaways from a live webinar on available emerging subcutaneous immunotherapy options for patients with cancer including:
Basic mechanism of action and role of hyaluronidase in subcutaneous immunotherapy formulation and available dosing/schedules
Available pharmacodynamics/pharmacokinetics, efficacy, and safety data for subcutaneous immunotherapy formulations
Current and potential models for administration of subcutaneous immunotherapy in the inpatient setting and day-to-day considerations
Presenters:
Kelly Romo, PharmD, BCOP
Manager, Oncology Medical Drug Management and Customer Initiatives
Blue Cross Blue Shield Michigan
Detroit, Michigan
Shawna Kraft, PharmD, BCOP
Clinical Pharmacist, Specialist
Michigan Medicine, Rogel Cancer Center
Clinical Associate Professor
University of Michigan College of Pharmacy
Ann Arbor, Michigan
Resources:
Consolidate your learning with a recording from an on-demand webcast, download the slides associated with this discussion, or read an expert text module or commentary on this topic. 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, hear Allison Butts, PharmD, BCOP and Danielle Roman, PharmD, BCOP, share their insights on the best practices for incorporating antibody–drug conjugates (ADCs) into clinical practice including:
An overview of ADC structure and mechanism of action
A topline review of data supporting the current FDA-approved indications for ADCs targeting HER2 and TROP-2 across multiple tumor types
An in-depth look at common and serious adverse events with each approved ADC along with an overview of management strategies
Editor’s note: On June 23, 2025, the FDA granted accelerated approval for a new indication for datopotamab deruxtecan, one of the antibody drug conjugates discussed in this podcast. Datopotamab deruxtecan is now also approved for adults with locally advanced or metastatic EGFR-mutated NSCLC who have received previous EGFR-targeted therapy and platinum-based chemotherapy. 
Program faculty:
Allison Butts, PharmD, BCOP
Pharmacist Manager, Oncology
Clinical Pharmacist, Breast Oncology
UK HealthCare
Markey Cancer Center
Lexington, Kentucky
Danielle Roman, PharmD, BCOP
Manager, Oncology Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania
Program page:
https://bit.ly/4lr7cT6

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast, Brett M. Elicker, MD, and David E. Griffith, MD, ATSF, FACCP, FRSM, discuss the pathophysiology of non–cystic fibrosis bronchiectasis (NCFBE), the patient burden, and best practices with diagnosing NCFBE, including:
The vicious vortex of NCFBE (ie, airway dysfunction, inflammation, infection)
Cough as the most significant symptom and burden
Imaging bronchiectasis with classic and inflammatory findings
Differentiating the causes of NCFBE to inform patient care
Presenters
Brett M. Elicker, MD
Professor of Clinical Radiology
Chief, Cardiothoracic Imaging Division
Department of Radiology & Biomedical Imaging
University of California, San Francisco
San Francisco, California
David E. Griffith, MD, ATSF, FACCP, FRSM
Professor of Medicine
Division of Mycobacterial and Respiratory Diseases
Department of Medicine
National Jewish Health
Denver, Colorado
Program page: 
https://bit.ly/4mZbYsm

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen in as Jonathan A. Bernstein, MD, and Ryan Haumschild, PharmD, MS, MBA, CPEL, discuss how to manage the multidisciplinary care of patients with systemic mastocytosis (SM) from both the allergy/immunology and pharmacy perspective, including:
Strategies to better identify patients presenting with features of SM to facilitate timely diagnosis
Current guideline-recommended treatment approaches
Emerging data on new targeted agents for SM
Pharmacist-led strategies to help patients achieve better outcomes (e.g., specialist referral, polypharmacy counseling, and anaphylaxis education)
Presenters
Jonathan A. Bernstein, MD
Professor of Medicine
Division of Rheumatology, Allergy and Immunology
Department of Internal Medicine
University of Cincinnati College of Medicine
Partner Advanced Allergy Services, LLC
Partner Bernstein Clinical Research Center, LLC
Cincinnati, Ohio
Ryan Haumschild, PharmD, MS, MBA, CPEL
Vice President of Pharmacy, Ambulatory
Emory Healthcare
Winship Cancer Institute
Atlanta, Georgia
Full link to program page:
https://bit.ly/3HcA8z2

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Allison Butts, PharmD, BCOP, reviews how pharmacists can help in providing comprehensive patient-centric care for patients with HR+/HER2- MBC and preexisting comorbid conditions, including:
Common comorbidities and complexities in managing patients with HR+/HER2- MBC
Treatment landscape for patients with HR+/HER2- MBC
Real-world studies in women with HR+/HER2- MBC
Mitigation and management of drug interactions and multidisciplinary team coordination treatment selection
Patient goals and coordinating with multidisciplinary team to maximize quality of life
Link to full program:
https://bit.ly/4jCQe38

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.